HRP20240288T1 - Tekući farmaceutski sastav koji sadrži ensifentrin i glikopirolat - Google Patents

Tekući farmaceutski sastav koji sadrži ensifentrin i glikopirolat Download PDF

Info

Publication number
HRP20240288T1
HRP20240288T1 HRP20240288TT HRP20240288T HRP20240288T1 HR P20240288 T1 HRP20240288 T1 HR P20240288T1 HR P20240288T T HRP20240288T T HR P20240288TT HR P20240288 T HRP20240288 T HR P20240288T HR P20240288 T1 HRP20240288 T1 HR P20240288T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
composition according
glycopyrrolate
ensifenthrin
Prior art date
Application number
HRP20240288TT
Other languages
English (en)
Croatian (hr)
Inventor
Peter Lionel Spargo
Phillip Andrew HAYWOOD
Edward James FRENCH
Original Assignee
Verona Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verona Pharma Plc filed Critical Verona Pharma Plc
Publication of HRP20240288T1 publication Critical patent/HRP20240288T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HRP20240288TT 2020-02-27 2021-02-26 Tekući farmaceutski sastav koji sadrži ensifentrin i glikopirolat HRP20240288T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2002786.8A GB202002786D0 (en) 2020-02-27 2020-02-27 Liquid pharmaceutical composition
EP21709782.3A EP4110292B1 (en) 2020-02-27 2021-02-26 Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate
PCT/GB2021/050496 WO2021171034A1 (en) 2020-02-27 2021-02-26 Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate

Publications (1)

Publication Number Publication Date
HRP20240288T1 true HRP20240288T1 (hr) 2024-05-24

Family

ID=70278709

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20240288TT HRP20240288T1 (hr) 2020-02-27 2021-02-26 Tekući farmaceutski sastav koji sadrži ensifentrin i glikopirolat

Country Status (25)

Country Link
US (1) US20230112220A1 (OSRAM)
EP (2) EP4306129A3 (OSRAM)
JP (2) JP7781762B2 (OSRAM)
KR (1) KR20220149669A (OSRAM)
CN (1) CN115279343A (OSRAM)
AU (1) AU2021227456A1 (OSRAM)
BR (1) BR112022016015A2 (OSRAM)
CA (1) CA3166952A1 (OSRAM)
DK (1) DK4110292T3 (OSRAM)
ES (1) ES2970571T3 (OSRAM)
FI (1) FI4110292T3 (OSRAM)
GB (1) GB202002786D0 (OSRAM)
HR (1) HRP20240288T1 (OSRAM)
HU (1) HUE065531T2 (OSRAM)
IL (1) IL295442A (OSRAM)
LT (1) LT4110292T (OSRAM)
MX (1) MX2022010014A (OSRAM)
PH (1) PH12022552278A1 (OSRAM)
PL (1) PL4110292T3 (OSRAM)
PT (1) PT4110292T (OSRAM)
RS (1) RS65330B1 (OSRAM)
SI (1) SI4110292T1 (OSRAM)
SM (1) SMT202400076T1 (OSRAM)
WO (1) WO2021171034A1 (OSRAM)
ZA (1) ZA202208763B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3231444T3 (pl) 2014-05-12 2020-05-18 Verona Pharma Plc Nowe leczenie
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
EP4609864A4 (en) * 2022-10-28 2026-02-18 Jiangsu Hengrui Pharmaceuticals Co Ltd PHARMACEUTICAL COMPOSITION CONTAINING AN ISOQUINOLINONE COMPOUND AND RELATED PREPARATION PROCESS
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2368413C (en) 1999-03-31 2008-07-29 Verona Pharma Plc Derivatives of pyrimido[6,1-a]isoquinolin-4-one
NZ587561A (en) * 2008-02-26 2012-10-26 Elevation Pharmaceuticals Inc Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations (an muscarinic antagnoist)
SI2968313T1 (en) 2013-03-15 2018-05-31 Verona Pharma Plc Combination of medicines
PT3332767T (pt) * 2014-09-15 2019-06-27 Verona Pharma Plc Formulação por inalação líquida compreendendo rpl554

Also Published As

Publication number Publication date
ES2970571T3 (es) 2024-05-29
JP2026035711A (ja) 2026-03-04
CN115279343A (zh) 2022-11-01
SI4110292T1 (sl) 2024-03-29
FI4110292T3 (fi) 2024-03-01
LT4110292T (lt) 2024-02-12
GB202002786D0 (en) 2020-04-15
KR20220149669A (ko) 2022-11-08
EP4110292A1 (en) 2023-01-04
MX2022010014A (es) 2022-10-18
JP7781762B2 (ja) 2025-12-08
SMT202400076T1 (it) 2024-03-13
EP4110292B1 (en) 2024-01-10
IL295442A (en) 2022-10-01
AU2021227456A1 (en) 2022-09-08
EP4306129A3 (en) 2024-04-17
DK4110292T3 (da) 2024-02-19
BR112022016015A2 (pt) 2022-10-11
RS65330B1 (sr) 2024-04-30
PH12022552278A1 (en) 2024-03-04
HUE065531T2 (hu) 2024-05-28
JP2023516630A (ja) 2023-04-20
WO2021171034A1 (en) 2021-09-02
PL4110292T3 (pl) 2024-05-20
US20230112220A1 (en) 2023-04-13
CA3166952A1 (en) 2021-09-02
ZA202208763B (en) 2024-01-31
PT4110292T (pt) 2024-01-31
EP4306129A2 (en) 2024-01-17

Similar Documents

Publication Publication Date Title
HRP20211035T1 (hr) Tekuća formulacija za inhalaciju koja sadrži rpl554
FI4110292T3 (fi) Nestemäinen farmaseuttinen koostumus, joka käsittää ensifentriiniä ja glykopyrrolaattia
JP2017528479A5 (OSRAM)
JP2023516630A5 (OSRAM)
ES2266322T3 (es) Nuevo uso de budesonida y formoterol.
NO20140823L (no) Anvendelse av et preparat omfattende formoterol og budesonid for forebyggelse eller behandling av en akutt astmatilstand
PE20120023A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
KR20150011807A (ko) 자일리톨계 항-점액성 조성물과 관련 방법 및 조성물
JP2006501133A5 (OSRAM)
HRP20241746T1 (hr) Stabilni pripravci askorbinske kiseline i postupci za njihovu uporabu
HRP20211515T1 (hr) Stabilni farmaceutski pripravak u fiksnoj dozi koji sadrži mometazon i olopatadin, namijenjen nazalnoj primjeni
JP2022550664A5 (OSRAM)
JP2013535472A5 (OSRAM)
US20100202979A1 (en) Compositions and methods for treatment of pulmonary diseases and conditions
Anderson et al. The protective effect of nedocromil sodium and other drugs on airway narrowing provoked by hyperosmolar stimuli: a role for the airway epithelium?
JP2005531528A5 (OSRAM)
PT100150A (pt) Formulacoes que contem esteroides
AU2012265231B2 (en) Nasal pharmaceutical formulation
CN118750472A (zh) 一种雷芬那辛吸入溶液及制备方法
TH2101002047A (th) องค์ประกอบเชิงเภสัชกรรมซึ่งประกอบรวมด้วย rpl554 ใน hfa-134a สำหรับการดำเนินการให้โดยการสูดดม
TH174318A (th) สูตรผสม
NZ729796B2 (en) Liquid inhalation formulation comprising rpl554
RU2021109697A (ru) Фармацевтические композиции, содержащие RPL554 в HFA-134A для введения посредством ингаляции
Mochizuki et al. Effect of inhaled amiloride on water-induced bronchoconstriction in asthmatic children.
NZ767295B2 (en) Liquid Inhalation Formulation Comprising RPL554